POXEL FRANCE (PXXLF) Stock Price, News & Analysis

Company Overview

Poxel France (OTCMKTS:PXXLF) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapies for metabolic diseases, primarily type 2 diabetes and nonalcoholic steatohepatitis (NASH). Headquartered in Lyon, France, the company focuses on small-molecule drug candidates designed to address underlying mitochondrial dysfunction and improve metabolic homeostasis. Poxel’s research platform leverages proprietary chemistry and pharmacology expertise to optimize safety and efficacy profiles of its lead compounds.

The company’s flagship product candidate is imeglimin, a first-in-class tetrahydrotriazine molecule that targets mitochondrial bioenergetics to enhance insulin secretion and improve insulin sensitivity. Imeglimin has received regulatory approval in Japan under the trade name Twymeeg® through a partnership with Sumitomo Pharma, marking the first global approval of a new class of oral antidiabetic agents in more than a decade. Poxel retains ex-U.S. and ex-Japan rights, with ongoing preparations for submissions in additional territories.

In addition to imeglimin, Poxel is advancing PXL065, a deuterium-stabilized form of pioglitazone, in clinical development for NASH. By selectively targeting the active R-enantiomer of pioglitazone, PXL065 aims to maximize therapeutic benefits on liver histology while reducing side effects associated with traditional thiazolidinediones. Early-stage clinical data support PXL065’s favorable safety profile and potential to address unmet needs in NASH, a rapidly growing indication with no approved therapies in major markets.

Poxel operates research and development facilities in France and maintains strategic collaborations to support its global development strategy. The company’s leadership team brings together expertise in metabolic disease research, regulatory affairs and commercial strategy, positioning Poxel to advance its pipeline through late-stage trials and toward potential regulatory submissions outside Japan. Poxel France shares trade on the OTC Markets under the ticker PXXLF, reflecting its commitment to transparency and engagement with the international investment community.

Key Stats

• Today's Range: $0.25 to $0.25
• 50-Day Range: $0.25 to $0.25
• 52-Week Range: $0.25 to $0.25
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXXLF Stock Analysis - Frequently Asked Questions

How have PXXLF shares performed this year?

POXEL FRANCE's stock was trading at $0.25 on January 1st, 2025. Since then, PXXLF stock has increased by 0.0% and is now trading at $0.25.

How do I buy shares of POXEL FRANCE?

Shares of PXXLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PXXLF
• CIK: N/A
• Web: www.poxel.com
• Phone: 33-4-37-37-20-10
• Fax: 043-770-8815
• Employees: 15
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $710 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.42